U.S. Markets open in 3 hrs

Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Supernus Pharmaceuticals Inc (SUPN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus Pharmaceuticals Inc has a market cap of $2.15 billion; its shares were traded at around $41.14 with a P/E ratio of 19.98 and P/S ratio of 5.82.

For the last quarter Supernus Pharmaceuticals Inc reported a revenue of $115.9 million, compared with the revenue of $88.44 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $408.9 million, an increase of 35.3% from last year. For the last five years Supernus Pharmaceuticals Inc had an average revenue growth rate of 80.9% a year.

The reported diluted earnings per share was $2.05 for the year, an increase of 89.8% from previous year. The Supernus Pharmaceuticals Inc enjoyed an operating margin of 35.33%, compared with the operating margin of 32.93% a year before. The 10-year historical median operating margin of Supernus Pharmaceuticals Inc is -140.17%. The profitability rank of the company is 6 (out of 10).

At the end of the fiscal year, Supernus Pharmaceuticals Inc has the cash and cash equivalents of $192.2 million, compared with $100.3 million in the previous year. The long term debt was $329.5 million. The interest coverage to the debt is 8. Supernus Pharmaceuticals Inc has a financial strength rank of 6 (out of 10).

At the current stock price of $41.14, Supernus Pharmaceuticals Inc is traded at 18.2% discount to its historical median P/S valuation band of $50.32. The P/S ratio of the stock is 5.82, while the historical median P/S ratio is 7.12. The stock gained 4.99% during the past 12 months.

CFO Recent Trades:

  • Sr VP, CFO Gregory S Patrick sold 20,000 shares of SUPN stock on 02/27/2019 at the average price of $41.53. The price of the stock has decreased by 0.94% since.

For the complete 20-year historical financial data of SUPN, click here.

This article first appeared on GuruFocus.